• 제목/요약/키워드: hepatoportal

검색결과 2건 처리시간 0.014초

흰쥐의 종양에 대한 단삼 추출물의 항종양 활성 (Antitumor Activity of Salvia miltiorrhiza Herbal Extract in Rat Tumor Model)

  • 박현정;안상건;김정상
    • 한국식품영양과학회지
    • /
    • 제36권4호
    • /
    • pp.400-404
    • /
    • 2007
  • 흰쥐 우측요부에 RK3E-ras cell주입으로 7일 이내에 종양이 발달하는 것을 관찰하고, 단삼 추출물을 제조하여 항종양 효과를 관찰하고자 1주 후부터 2주 동안 육종 부위에 투여 후 종양의 크기와 무게를 측정하고 조직학적인 관찰을 통하여 암세포의 발달과 암전이 유무를 살펴보았다. 암종의 크기는 대조군에 비하여 단삼 추출물을 투여한 실험군에서 현저히 감소(p<0.01)하였으며, 암종의 중량 또한 실험군에서 현저히 감소(p<0.01)하였다. 조직학적 관찰 결과 종양을 둘러싸고 있는 섬유막은 대조군에 비하여 실험군에서 발달 해 있었으며, 암세포의 밀도는 실험군에 비하여 대조군에서 높았다. 간조직을 관찰한 결과 대조군의 간문맥 주변에서 전이된 것으로 보이는 암세포들이 다수 관찰되었다. 이와 같은 결과를 토대로 단삼 추출물이 항종양효과가 있다고 사료된다.

인터루킨-2의 제제설계를 위한 체내 동태학적 연구 (Pharmacokinetic Preformulation Study of rH IL-2)

  • 서민석;심창구;권종범;나도선;이선복;함경수;한문희
    • 약학회지
    • /
    • 제34권4호
    • /
    • pp.238-243
    • /
    • 1990
  • Pharmacokinetic characteristics of recombinant human interleukin-2 (rH IL-2) wre studied in the rat. First, different doses of rH IL-2 ranging from 6,400 to 1,600,000 U/kg were injected intravenously and the effect of dose size on the pharmacokinetics was examined. There was no dose dependency in the pharmacokinetics of rHIL-2 in the dose range of 6,400-40,000 U/kg. But at the dose of 1,600,000 U/kg, there was a severe hemolysis throughout the experiment and the pharmacokinetic parameters such as Vdss and CLt were significantly increased compared to those obtained from lower doses. It also showed that this drug is hardly distributed to the peripheral tissues and hardly eliminated from the body, since the valume of distribution (Vdss) and total body clearance (CLt) were 45-75 ml/kg and 1-2 ml/min/kg, respectively. The Vdss is close to the actual plasma volume and the CLt is less than glomerular filtration rate (GFR). Therefore it seemed that rH IL-2 is distributed only in the plasma pool and hardly filtered in the kidney due to its very large molecular weight. Second, rH IL-2 was administered to the rat via several routes such as hepatic portal vein (PV), intraperitoneal (IP), peroral (PO) and intranasal (IN) routes. The bioavailabilities (BA) of PV, IP, PO and IN routes were 96.8, 4.9, 0 and 0.1%, respectively. The addition of some nasal absorption enhancers such as taurocholate, taurodeoxycholate, glycocholate and glycodeoxycholate did not increase the BA of intranasaly administered rH IL-2. The result is contrast to the effect of these bile salts on the nasal absorption of ${\alpha}-inteferon$. Considering it together with the pharmacokinetic parameters, very large molecular weight of rH IL-2 seemed again to be the cause to very poor membrane permeability.

  • PDF